Neladalkib (NVL-655) is an investigational next-generation precision kinase inhibitor that has been granted Priority Review and Breakthrough Therapy Designations by the Food and Drug Administration for advanced ALK-positive non-small cell lung cancer. Following GSK's acquisition of its developer, regulatory reviews target completion dates with commercial launches anticipated following final administrative clearances.